When was the last time you felt genuinely taken seriously by a gynecologist?
Imagine going to a doctor because your periods are so painful that you cannot get out of bed, or because they are too long or irregular. You have missed work, cancelled plans, you always have brain fog, tiredness, cravings, thyroid issues, and spent years trying to understand what is happening to your body. You explain your symptoms, hoping for answers. Instead, you are told that period pain is normal, that you might be stressed, or that you should change your lifestyle.
Now imagine visiting a doctor because you are struggling to get pregnant. Suddenly, there seems to be a greater urgency to find out what is wrong.
Endometriosis and PMOS reveal how healthcare prioritizes women’s reproductive capacity over their everyday well-being.This is not simply a hypothetical comparison. Recent research in the Netherlands reveals a striking difference in how long it takes to diagnose endometriosis depending on the symptoms patients initially present with. Getting diagnosed takes 12 years if the problem is pain, but 3 years if it is infertility (de Kok et al., 2026).
Women Experience Medical Gaslighting
Unfortunately, feeling unheard is common among people with these conditions. A study published in 2026 examined the healthcare experiences of 468 people with endometriosis. Four in five (80.8%) reported at least one distressing medical interaction, and the most common type by far was gaslighting, dismissal, and gatekeeping, which accounted for 60% of the experiences described (Mosterd et al., 2026).
Participants described having their pain normalized, symptoms questioned, or concerns minimized. Although the self-selected sample cannot represent everyone with endometriosis, the findings point to experiences that deserve greater attention. Sometimes dismissal is not an outright refusal of care. It can be the repeated suggestion to lose weight, reduce stress, or exercise more without adequately investigating persistent symptoms or responding to treatment concerns. Of course, lifestyle recommendations can be valuable. But they should complement appropriate medical care, not replace it.
Twelve Years for Pain. Three Years for Infertility.
A 2026 study published in Reproductive BioMedicine Online examined diagnostic delays among 837 people with endometriosis across eleven Dutch hospitals (de Kok et al., 2026). Endometriosis affects approximately one in ten women of reproductive age, around 190 million people worldwide (World Health Organization, 2023). It can cause debilitating menstrual pain, chronic pelvic pain, fatigue, and difficulties with daily activities, relationships, and work.
Yet in that same study, fewer than one in five patients (19.7%) had endometriosis named by their GP as a possible diagnosis at the point of referral to specialist care (de Kok et al., 2026).
Perhaps we should be asking why severe menstrual pain is still so easily normalized in the first place. When pain is treated as something women are simply expected to endure, it stops being seen as a medical problem worth investigating which is exactly how a symptom becomes a twelve-year wait. This is the thread running through every figure above. The issue is not only how slowly these conditions are diagnosed, but a mindset that questions whether women’s pain warrants diagnosis at all.
Women Prioritize Metabolic Health Over Infertility
Endometriosis is not the only condition that exposes the limitations of how women’s health is understood. For decades, polycystic ovary syndrome (PCOS) has been primarily associated with irregular periods, ovarian function, and infertility. But the condition also involves metabolic and hormonal disturbances that can affect cardiovascular health, insulin resistance, skin, hair, and psychological well-being.
In 2026, an international medical consensus proposed renaming PCOS polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its complex, multisystem nature (Teede et al., 2026).
The change is more than a matter of terminology. It acknowledges that the previous name did not adequately represent a condition affecting multiple systems throughout the body (Teede et al., 2026).
A 2024 international study involving 1,278 women with PCOS and 1,474 healthcare professionals examined priorities for future research. Among patients, 71% prioritized metabolic health, including insulin resistance and diabetes. Another 69% selected symptoms associated with elevated androgen levels, such as acne, hair loss, and excessive hair growth. Infertility was selected by 63% (Teede et al., 2024).
Fertility clearly matters to many women. But so do their long-term health, physical symptoms, confidence, and quality of life. These findings challenge the tendency to approach complex conditions primarily through their reproductive consequences.
We Are Women, Not Just Potential Mothers
For both endometriosis and PCOS/PMOS, hormonal contraceptives are commonly prescribed to manage symptoms. Standard clinical practice guidelines recommend combined hormonal contraceptives and progestogens as first-line medical therapies to reduce endometriosis-associated pain before or alongside surgical evaluation (Becker et al., 2022). They can effectively reduce menstrual pain, regulate bleeding, and improve hormonal symptoms.
But what happens when the treatment itself starts affecting someone’s quality of life?
Reduced sexual desire, vaginal dryness, headaches, and mood changes are among the concerns associated with some hormonal contraceptives. A systematic review of 36 studies involving 13,673 women found that approximately 15% of combined oral contraceptive users reported a decrease in libido (Pastor et al., 2013).
A more recent review also identified potential negative effects on sexual arousal and vaginal lubrication, particularly with certain antiandrogenic formulations (Krapf & Goldstein, 2024).
Some people report concentration difficulties or brain fog, although research has not established a clear causal relationship. Other effects, such as fluid retention or headaches, can vary between individuals and contraceptive formulations.
More serious risks also exist. Combined hormonal contraceptives are associated with a small but established increase in blood-clot risk: across two large UK primary care databases, current use was linked to roughly six to fourteen extra cases of venous thromboembolism per 10,000 women per year, depending on the progestogen (Vinogradova et al., 2015). Rare liver complications, including hepatocellular adenoma, have also been documented with prolonged oestrogen exposure, particularly through oral contraceptives (Cazzagon et al., 2026). These risks are uncommon, but they matter when choosing a treatment that may be used for years.
The problem is not that the pill is offered. It is when treatment becomes a prescription without sufficient discussion, follow-up, or alternatives. Managing symptoms should not mean accepting a different set of problems without being heard.
We need more research to understand exactly why this difference exists. But we already know that debilitating pain deserves timely investigation, regardless of whether someone wants children. Endometriosis and PMOS are distinct conditions, yet both expose the same underlying problem in how women’s health is approached, where reproductive capacity is often prioritised over women’s pain, health, and overall well-being.
Women’s healthcare must take women seriously as people, not only as potential mothers.
Our health matters before pregnancy, during pregnancy, after pregnancy, and whether pregnancy is ever part of our lives at all.
References
Becker, C. M., Bokor, A., Heikinheimo, O., Horne, A., Jansen, F., Kiesel, L., King, K., Kvaskoff, M., Nap, A., Petersen, K., Saridogan, E., Tomassetti, C., van Hanegem, N., Vulliemoz, N., Vermeulen, N., & ESHRE Endometriosis Guideline Group. (2022). ESHRE guideline: Endometriosis. Human Reproduction Open, 2022(2), hoac009. https://doi.org/10.1093/hropen/hoac009
Cazzagon, N., Gambato, M., Brunetto, M. R., Villa, E., Burra, P., Floreani, A., & Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). (2026). Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy. Liver International, 46(2), e70509. https://doi.org/10.1111/liv.70509
de Kok, L., Boersen, Z., Coppus, S., van Haaps, A., van Hanegem, N., Klinkert, E., Maas, J., Mijatovic, V., Smeets, M., Steensma, A., Teklenburg, G., van Vliet, H., Braat, D., Schers, H., & Nap, A. (2026). Diagnostic delay in endometriosis: Is there any progress? Reproductive BioMedicine Online, 53(1), 105405. https://doi.org/10.1016/j.rbmo.2025.105405
Krapf, J. M., & Goldstein, A. T. (2024). Combined estrogen-progestin oral contraceptives and female sexuality: An updated review. Sexual Medicine Reviews, 12(3), 307–320. https://pubmed.ncbi.nlm.nih.gov/38515302/
Mosterd, D., Van Niekerk, L., Mikocka-Walus, A., Leonardi, M., Stanley, K., & Evans, S. (2026). “Belittled” and “Broken”: Distressing Medical Interactions in Endometriosis Healthcare: A Mixed Methods Study. Women’s Reproductive Health, 13(3), 863–877. https://doi.org/10.1080/23293691.2025.2602849
Pastor, Z., Holla, K., & Chmel, R. (2013). The influence of combined oral contraceptives on female sexual desire: A systematic review. European Journal of Contraception & Reproductive Health Care, 18(1), 27–43. https://doi.org/10.3109/13625187.2012.728643
Teede, H. J., Bahri Khomami, M., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M. F., Patil, M., Rees, D. A., Berry, L., Cree, M. G., Zhao, H., Norman, R. J., Dokras, A., & Piltonen, T., on behalf of the Global Name Change Consortium. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process. The Lancet, 407(10545), 2329–2339. https://doi.org/10.1016/S0140-6736(26)00717-8
Teede, H. J., Gibson, M., Laven, J., Dokras, A., Moran, L. J., Piltonen, T., Costello, M., Mousa, A., Joham, A. E., & Tay, C. T., on behalf of the International PCOS Network. (2024). International PCOS guideline clinical research priorities roadmap: A co-designed approach aligned with end-user priorities in a neglected women’s health condition. eClinicalMedicine, 78, 102927. https://pmc.ncbi.nlm.nih.gov/articles/PMC11614868/
Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2015). Use of combined oral contraceptives and risk of venous thromboembolism: Nested case-control studies using the QResearch and CPRD databases. BMJ, 350, h2135. https://doi.org/10.1136/bmj.h2135
World Health Organization. (2023). Endometriosis [Fact sheet]. https://www.who.int/news-room/fact-sheets/detail/endometriosis
